Enanta Pharma (ENTA) Misses Q1 EPS by 175c

Enanta Pharma (NASDAQ: ENTA) reported Q1 EPS of ($1.58), $1.75 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $18 million versus the consensus estimate of $21.28 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits